AVISCERA BIOSCIENCE  
AVISCERA BIOSCIENCE  
line decor
  HOME  ::  
line decor
   
 

CD25/IL-2R alpha (Soluble) ELISA Kit, Protein, Antibody

Alternative name:

  • CD25
  • IL-2 Receptor alpha
Soluble CD25/IL-2R alpha (Human) ELISA Kit
Code No.: SK00761-01
Size: 96 T
Price: $420.00
Standard range:6.25-400 pg/ml
Sensitivity: 3 pg/ml
Sample Type:serum, plasma
Sample require: 100 ul per well
Intra-CV: 6-8%
Inter-CV: 8-12%
Data Sheet: PDF
Anti Soluble CD25/IL-2RA (Human) IgG
Code No.: A00761-02-50
Size: 50 ug
Price: $320.00 USD
Host: Rabbit
Antigen: human CD25 ECD Rec.
Ab Type: Polyclonal IgG
Purification: Protein A
Applications: E
Working Dilution: 1 ug/ml
Data Sheet: PDF
Anti Soluble CD25/IL-2RA (Mouse) IgG
Code No.: A00761-03-50
Size: 50 ug
Price: $320.00 USD
Host: Rabbit
Antigen: Mouse CD25 ECD Rec.
Ab Type: Polyclonal IgG
Purification: Protein A
Applications: E
Working Dilution: 1 ug/ml
Data Sheet: PDF

 

Name
Code No.
Size
Price ($)
Soluble CD25/ IL_2R alpha (Human) ELISA Kit
96 T
420.00
Soluble CD25/ IL_2R alpha (Human) ELISA Kit
SK00761-02
96 T
420.00
Soluble CD25/ IL_2R alpha (Mouse) ELISA Kit
SK00761-03
96 T
490.00
Soluble CD25/IL-2R alpha (Human) Rec
00761-06-1000
1 mg
Inquire
Soluble CD25/IL-2R alpha (Mouse) Rec
00761-03-10
10 ug
180.00
Anti Soluble CD25 (Human) IgG
A00761-02-50
50 ug
350.00
Anti Soluble CD25 (Human) IgG Biotinylated
A00761-02-50B
50 ug
360.00
Anti Soluble CD25 (Mouse) IgG
A00761-03-50
50 ug
350.00
Anti Soluble CD25 (Mouse) IgG Biotinylated
A00761-03-50B
50 ug
390.00
       
       
References

Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25

. The cytotoxic T lymphocyte antigen-4 (CTLA-4)-blocking antibody ipilimumab induces immune-mediated long-term control of metastatic melanoma in a fraction of patients. Although ipilimumab undoubtedly exerts its therapeutic effects via immunostimulation, thus far clinically useful, immunologically relevant biomarkers that predict treatment efficiency have been elusive. Here, we show that neutralization of IL-2 or blocking the a and subunits of the IL-2 receptor (CD25 and CD122, respectively) abolished the antitumor effects and the accompanying improvement of the ratio of intratumoral T effector versus regulatory cells (Tregs), which were otherwise induced by CTLA-4 blockade in preclinical mouse models. CTLA-4 blockade led to the reduction of a suppressive CD4(+) T cell subset expressing Lag3, ICOS, IL-10 and Egr2 with a concomitant rise in IL-2-producing effector cells that lost FoxP3 expression and accumulated in regressing tumors. While recombinant IL-2 improved the therapeutic efficacy of CTLA-4 blockade, the decoy IL-2 receptor a (IL-2Ra, sCD25) inhibited the anticancer effects of CTLA-4 blockade. In 262 metastatic melanoma patients receiving ipilimumab, baseline serum concentrations of sCD25 represented an independent indicator of overall survival, with high levels predicting resistance to therapy. Altogether, these results unravel a role for IL-2 and IL-2 receptors in the anticancer activity of CTLA-4 blockade. Importantly, our study provides the first immunologically relevant biomarker, namely elevated serum sCD25, that predicts resistance to CTLA-4 blockade in patients with melanoma. Hannani D., et al. Cell Res. 2015 Feb;25(2):208-24

Plasma concentrations of soluble IL-2 receptor a (CD25) are increased in type 1 diabetes and associated with reduced C-peptide levels in young patients

AIMS/HYPOTHESIS:Type 1 diabetes is a common autoimmune disease that has genetic and environmental determinants. Variations within the IL2 and IL2RA (also known as CD25) gene regions are associated with disease risk, and variation in expression or function of these proteins is likely to be causal. We aimed to investigate if circulating concentrations of the soluble form of CD25, sCD25, an established marker of immune activation and inflammation, were increased in individuals with type 1 diabetes and if this was associated with the concentration of C-peptide, a measure of insulin production that reflects the degree of autoimmune destruction of the insulin-producing beta cells. METHODS:We used immunoassays to measure sCD25 and C-peptide in peripheral blood plasma from patient and control samples. RESULTS:We identified that sCD25 was increased in patients with type 1 diabetes compared with controls and replicated this result in an independent set of 86 adult patient and 80 age-matched control samples (p=1.1710(-3)). In 230 patients under 20 years of age, with median duration-of-disease of 6.1 years, concentrations of sCD25 were negatively associated with C-peptide concentrations (p=4.810(-3)). CONCLUSIONS/INTERPRETATION:The 25% increase in sCD25 in patients, alongside the inverse association between sCD25 and C-peptide, probably reflect the adverse effects of an on-going, actively autoimmune and inflammatory immune system on beta cell function in patients.Downes K., et al. Diabetologia. 2014 Feb;57(2):366-72